European Medicines Agency (EMA) updates general guidelines on development of medicinal products for Major Depressive Disorder (MDD) to include a section on psychedelic therapy.

Psychedelic Health provide the update With up to two-thirds of MDD patients not responding to current therapies, there is an urgent need for new and innovative treatments.  The area of psychedelic research has in recent years produced increasing clinical evidence that points towards these therapies as being potentially efficacious treatments for the condition. The guidelines […]

Go to Source

Powered by WPeMatico